These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 26586007)
1. Atypical clinical and radiological course of a patient with Canavan disease. Sarret C; Boespflug-Tanguy O; Rodriguez D Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007 [TBL] [Abstract][Full Text] [Related]
2. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Eke GH; Iscan A; Cece H; Calik M Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636 [TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
5. Atypical MRI findings in Canavan disease: a patient with a mild course. Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711 [TBL] [Abstract][Full Text] [Related]
6. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion. Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223 [TBL] [Abstract][Full Text] [Related]
7. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821 [TBL] [Abstract][Full Text] [Related]
9. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
10. [Canavan disease or N-acetyl aspartic aciduria: a case report]. Boughamoura L; Chaabane F; Tilouche S; Chabchoub I; Kabachi N; Tlili K; Yacoub M; Essoussi AS Arch Pediatr; 2007 Feb; 14(2):173-6. PubMed ID: 17196380 [TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900 [TBL] [Abstract][Full Text] [Related]
12. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Janson CG; McPhee SW; Francis J; Shera D; Assadi M; Freese A; Hurh P; Haselgrove J; Wang DJ; Bilaniuk L; Leone P Neuropediatrics; 2006 Aug; 37(4):209-21. PubMed ID: 17177147 [TBL] [Abstract][Full Text] [Related]
13. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
14. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
15. Leukodystrophy with multiple beaded periventricular cysts: unusual cranial MRI results in Canavan disease. Drenckhahn A; Schuelke M; Knierim E J Inherit Metab Dis; 2015 Sep; 38(5):983-4. PubMed ID: 25647544 [TBL] [Abstract][Full Text] [Related]
16. Novel mutation in an Egyptian patient with infantile Canavan disease. Zaki OK; El Abd HS; Mohamed SA; Zayed H Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958 [TBL] [Abstract][Full Text] [Related]
17. An atypical case of Canavan disease with stroke-like presentation. Delaney KE; Kralik SF; Hainline BE; Golomb MR Pediatr Neurol; 2015 Feb; 52(2):218-21. PubMed ID: 25497124 [TBL] [Abstract][Full Text] [Related]
18. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
19. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related]
20. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]